McKesson Acquires Precision Medicine Group for $2.25 Billion to Bolster Oncology Division
McKesson Corporation (NYSE:MCK) announced the acquisition of privately-held Precision Medicine Group in a deal valued at approximately $2.25 billion, aiming to strengthen its oncology and specialty care offerings. The move aligns with McKesson's ongoing strategy to divest non-core assets while investing in high-growth areas such as clinical research and commercialization services for biopharma companies. Precision Medicine Group provides laboratory testing, clinical trial execution, and drug development support that will integrate into McKesson’s Oncology & Multispecialty segment. CEO Brian Tyler highlighted the acquisition's potential to enhance capabilities across these domains. The deal is part of a broader capital recycling strategy; earlier this year, McKesson sold a stake in its medical-surgical business for $1.25 billion. Analysts note that while the transaction supports strategic growth, it may not immediately transform company-wide performance due to integration risks and lack of an announced timeline. The acquisition is expected to gradually contribute to the Oncology & Multispecialty segment’s revenue, which rose 33% in Q1 fiscal 2026.
Tickers: $MCK
Topics: Corporate Strategy Healthcare Oncology Pharmaceuticals